Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19882983rdf:typepubmed:Citationlld:pubmed
pubmed-article:19882983lifeskim:mentionsumls-concept:C0003232lld:lifeskim
pubmed-article:19882983lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:19882983lifeskim:mentionsumls-concept:C0006968lld:lifeskim
pubmed-article:19882983lifeskim:mentionsumls-concept:C2699902lld:lifeskim
pubmed-article:19882983pubmed:issue3lld:pubmed
pubmed-article:19882983pubmed:dateCreated2009-11-3lld:pubmed
pubmed-article:19882983pubmed:abstractTextTebipenem pivoxil (TBPM-PI), the first oral carbapenem antibiotic both in Japan and abroad, was examined on its convulsive liability. We used ICR male mice and Sprague-Dawley male rats to examine the pro-convulsive effect and anticonvulsive effect of TBPM-PI and its active metabolite, TBPM. (1) When mice were treated with TBPM-PI (30-1000 mg/kg, p.o.) or TBPM (10-300 mg/kg, i.v.), no convulsion was noted at any dose level. When rats were treated with TBPM (300 mg/kg, i.v.), no convulsant effects were noted in electroencephalography or behavioral observation. In intraventricular injection of TBPM in mice, clonic convulsion was observed in 7/10 animals at 100 microg but no effect at 30 microg. On the other hand, the administration of 10/10 microg imipenem/cilastatin (IPM/CS) resulted in clonic convulsion in all animals and tonic convulsion in 3/10 animals, and 4/10 animals died. The administration of 100 microg meropenem did not cause any effects. (2) When mice were co-administered with pentylenetetrazole (45 mg/kg: maximum dose level at which no convulsion is induced) and TBPM-PI (30-300 mg/kg, p.o.) or TBPM (300 mg/kg, i.v.), convulsion enhancing effect was not noted. On the other hand, the co-administration of pentylenetetrazole with IPM/CS (300/300 mg/kg, i.v.) enhanced a convulsive effect of pentylenetetrazole. (3) When mice were treated with TBPM-PI (30-300 mg/kg, p.o.) or TBPM (100 mg/kg, i.v.), inhibitory effect was not noted on convulsions induced by electrostimulation, pentylenetetrazole or strychinine. In conclusion, there were no pro-convulsive effects or anticonvulsive effect in the oral administration of TBPM-PI or intravenous administration of TBPM. Pro-convulsive effect was observed in the intraventricular injection of TBPM as in the case of other carbapenem antibiotics, but such action was weaker than that in IPM/CS administration. Accordingly, the risk of occurrence of convulsion related to TBPM-PI administration was low compared to IPM/CS administration, and TBPM-PI was considered to be less potential to induce convulsions in clinical use.lld:pubmed
pubmed-article:19882983pubmed:languagejpnlld:pubmed
pubmed-article:19882983pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:citationSubsetIMlld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19882983pubmed:statusMEDLINElld:pubmed
pubmed-article:19882983pubmed:monthJunlld:pubmed
pubmed-article:19882983pubmed:issn0368-2781lld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:SuzukiHisashi...lld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:YagiYukihiroYlld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:KurataYasushi...lld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:KurosawaTohru...lld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:ShibasakiShig...lld:pubmed
pubmed-article:19882983pubmed:authorpubmed-author:NawaToruTlld:pubmed
pubmed-article:19882983pubmed:issnTypePrintlld:pubmed
pubmed-article:19882983pubmed:volume62lld:pubmed
pubmed-article:19882983pubmed:ownerNLMlld:pubmed
pubmed-article:19882983pubmed:authorsCompleteYlld:pubmed
pubmed-article:19882983pubmed:pagination241-52lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:meshHeadingpubmed-meshheading:19882983...lld:pubmed
pubmed-article:19882983pubmed:year2009lld:pubmed
pubmed-article:19882983pubmed:articleTitle[Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil].lld:pubmed
pubmed-article:19882983pubmed:affiliationApplied Pharmacology Research Labs., Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd.lld:pubmed
pubmed-article:19882983pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19882983pubmed:publicationTypeEnglish Abstractlld:pubmed